In contrast, IL-12RB2 polymorphism shows a protective effect for SRDs, including SLE and SS, potentially regulating IL-12 receptor function and moderating immune responses, thus possibly reducing the severity or prevalence of SRDs. This evidence concerns the gene IL12RB2 and synovial sarcoma.